IVERIC bio Inc.
News
Astellas Pharma completes acquisition of Iveric Bio
Pharmaceutical Business Review In April this year, Astellas Pharmas subsidiary agreed to buy 100% of the outstanding shares ofIveric Biofor$40 per share in cash for a total equity value of about\nThe post Astellas Pharma completes acquisition of Iveric Bio appeared first on Pharmaceutical Business review...\n more…
Astellas Completes Acquisition of Iveric Bio
PR Newswire Astellas Completes Acquisition of Iveric Bio Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J., July 11, 2023 TOKYO and PARSIPPANY, N.J., July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, 'Astellas') today...\n more…
IVERIC bio, Inc. (NASDAQ:ISEE) COO Sells $789,000.00 in Stock
Zolmax IVERIC bio, Inc. (NASDAQ:ISEE Free Report) COO Keith Westby sold 20,000 shares of the businesss stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $39.45, for a total value of $789,000.00. Following the transaction, the chief operating officer now ...\n more…
Rothschild Investment Corp IL Buys 1,450 Shares of IVERIC bio, Inc. (NASDAQ:ISEE)
Zolmax Rothschild Investment Corp IL boosted its holdings in shares of IVERIC bio, Inc. (NASDAQ:ISEE Free Report) by 13.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,200 shares of the companys stock ...\n more…
IVERIC bio (NASDAQ:ISEE) Now Covered by Analysts at StockNews.com
Ticker Report StockNews.com began coverage on shares of IVERIC bio (NASDAQ:ISEE Free Report) in a report issued on Thursday. The firm set a sell rating on the stock. Several other analysts have also issued reports on the company. Morgan Stanley lowered IVERIC bio from an overweight&#...\n more…
IVERIC bio, Inc. (NASDAQ:ISEE) COO Sells $789,000.00 in Stock
Ticker Report IVERIC bio, Inc. (NASDAQ:ISEE Free Report) COO Keith Westby sold 20,000 shares of the companys stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $39.45, for a total transaction of $789,000.00. Following the completion of the sale, the chief ...\n more…